Clinical Trial

A Phase Ⅲ Clinical Study of SNA02-48 Injection

Name: A Phase Ⅲ Clinical Study of SNA02-48 Injection — clinical trial record (NCT07633119)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.

Trial Details

NCT Number	NCT07633119
Lead Sponsor	Sinovac Life Sciences Co., Ltd.
Conditions	Tetanus
Enrollment	600 participants
Start Date	2026-06-28
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-08